ArticleAmerican journal of translational research2024
Levofloxacin combined with azithromycin shows greater efficacy in cervicitis treatment compared to azithromycin monotherapy.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy of levofloxacin combined with azithromycin in the treatment of cervicitis and its effect on serum inflammatory markers.
methodsA retrospective analysis was conducted on the clinical records of 102 patients with cervicitis treated at Gansu Provincial Maternity and Child-care Hospital between March 2022 and March 2023. The control group (47 patients) received azithromycin, while the study group (55 patients) was treated with a combination of levofloxacin and azithromycin. Serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP) were measured before treatment and after two weeks. The efficacy, adverse reaction rate, and recurrence of cervicitis over a 6-month follow-up period were analyzed. A multiple logistic regression was performed to identify factors influencing recurrence.
resultsPrior to treatment, no significant differences were observed between the two groups in IL-6, TNF-α, or CRP levels (all P>0.05). After treatment, both groups showed significant reductions in these markers (all P<0.0001), with the study group exhibiting more pronounced decreases (P<0.0001). The overall response rate in the study group was significantly higher than that of the control group (P=0.041). No significant difference in the incidence of adverse reactions was found between the groups (P=0.551). The recurrence rate of cervicitis was significantly higher in the control group compared to the study group (P=0.022). Logistic regression analysis identified disease severity (P=0.014, OR: 8.616; CI: 1.543-48.096), post-treatment IL-6 (P=0.003, OR: 17.573; CI: 2.720-113.531), post-treatment CRP (P=0.039, OR: 5.731; CI: 1.089-30.157), and post-treatment TNF-α (P=0.001, OR: 20.547; CI: 3.210-131.518) as independent predictors of recurrence.
conclusionLevofloxacin combined with azithromycin is more effective than azithromycin monotherapy in treating cervicitis. The combination significantly reduces inflammatory responses and recurrence rates without increasing adverse effects, making it a valuable option for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.